No Data
Allgens Medical Technology CO., LTD.'s (SHSE:688613) Popularity With Investors Is Under Threat From Overpricing
Aojing Healthcare: Aojing Healthcare: Report for the Third Quarter of 2024
Ojing Healthcare: third quarter report 2024
Aokes Medical (688613.SH) released its performance for the first three quarters, with a net income of 4.8882 million yuan, a year-on-year decrease of 90.95%.
Aokang Medical (688613.SH) disclosed its third quarter report for 2024, achieving operating revenue in the first three quarters...
OJE Medical (688613.SH): The net income in the first three quarters is approximately 4.89 million yuan, a decrease of 90.95% year-on-year.
On October 28, Ogintech Medical (688613.SH) announced that the revenue for the first three quarters of 2024 was approximately 0.148 billion yuan, a decrease of 19.22% year-on-year; the net income attributable to the shareholders of the listed company was approximately 4.89 million yuan, a decrease of 90.95% year-on-year; and the basic earnings per share was 0.04 yuan.
Both Individual Investors Who Control a Good Portion of Allgens Medical Technology CO., LTD. (SHSE:688613) Along With Institutions Must Be Dismayed After Last Week's 15% Decrease
Declining Stock and Decent Financials: Is The Market Wrong About Allgens Medical Technology CO., LTD. (SHSE:688613)?
